Elizabeth Anne Pomfret
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Elizabeth Anne Pomfret has a total of 134 co-authors. Here are the top co-authors by number of shared publications:
- Jesse D. Schold
Department of Surgery, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA
11 shared publications - James J. Pomposelli
Division of Transplant Surgery, Department of Surgery, Tufts Medical Center, Boston, Massachusetts, USA
8 shared publications - Deena Brosi
Division of Transplant Surgery, Department of Surgery, University of Colorado Anschutz Medical Campus, Aurora, Colorado; Colorado Center for Transplantation Care (CCTCARE), Research and Education, Division of Transplant Surgery, Department of Surgery, Anschutz Medical Campus, University of Colorado, Aurora, Colorado
6 shared publications - Jessica L. Saben
Natera, Inc. Austin Texas USA
6 shared publications - Rocio Lopez
Division of Transplant Surgery, Department of Surgery, University of Colorado Anschutz Medical Campus, Aurora, Colorado; Colorado Center for Transplantation Care (CCTCARE), Research and Education, Division of Transplant Surgery, Department of Surgery, Anschutz Medical Campus, University of Colorado, Aurora, Colorado
6 shared publications - Susana Arrigain
Department of Surgery, University of Colorado Anschutz Medical Campus, Aurora, Colorado
6 shared publications
Latest Publications
- Open Access
- 26 September 2026
- Published by MDPI AG in Biomedicines
- Vol. 14 (10) , 2180
Bivalent CD47 Immunotoxin for Targeted Therapy of Lung Cancer
Background/Objectives: Lung cancer is the leading cause of cancer-related death in the world, with ~2.5 million people diagnosed and ~1.5 million deaths each year. While the last two decades have yielded substantial progress, with systemic targeted and immune therapies improving treatment responses in subgroups of patients with advanced and refractory lung cancer, there is still a dire unmet clinical need to develop more effective therapies with durable responses. CD47 receptors are overexpressed on the surface of a variety of malignant tumor cells, including lung cancer. Although there has been increasing interest in developing targeting antibodies against CD47 for immunotherapy, they failed clinical trials due to their dose-limiting toxicities, primarily hematopoietic toxicity. Methods: Recently, using a unique diphtheria toxin-resistant Pichia pastoris yeast expression system, we developed a diphtheria toxin-based bivalent CD47 immunotoxin (bi-CD47-IT) for targeted therapy of CD47+ cancers. In this study, we extended application of the targeted therapy bi-CD47-IT to a solid tumor, specifically lung cancer. Results: Bi-CD47-IT demonstrated compelling preclinical efficacy in multiple non-small cell lung cancer (NSCLC) cell line-derived xenograft (CDX) and patient-derived xenograft (PDX) mouse models, including subcutaneous, orthotopic, metastatic, and humanized models. Conclusions: This study demonstrates the remarkable preclinical activity of bi-CD47-IT against various lung cancer models, making bi-CD47-IT a novel and promising therapeutic approach for NSCLC.
- 26 September 2026
- Published by MDPI AG in Biomedicines
- Vol. 14 (10) , 2180
Open AccessBivalent CD47 Immunotoxin for Targeted Therapy of Lung Cancer
Background/Objectives: Lung cancer is the leading cause of cancer-related death in the world, with ~2.5 million people diagnosed and ~1.5 million deaths each year. While the last two decades have yielded substantial progress, with systemic targeted and immune therapies improving treatment responses in subgroups of patients with advanced and refractory lung cancer, there is still a dire unmet clinical need to develop more effective therapies with durable responses. CD47 receptors are overexpressed on the surface of a variety of malignant tumor cells, including lung cancer. Although there has been increasing interest in developing targeting antibodies against CD47 for immunotherapy, they failed clinical trials due to their dose-limiting toxicities, primarily hematopoietic toxicity. Methods: Recently, using a unique diphtheria toxin-resistant Pichia pastoris yeast expression system, we developed a diphtheria toxin-based bivalent CD47 immunotoxin (bi-CD47-IT) for targeted therapy of CD47+ cancers. In this study, we extended application of the targeted therapy bi-CD47-IT to a solid tumor, specifically lung cancer. Results: Bi-CD47-IT demonstrated compelling preclinical efficacy in multiple non-small cell lung cancer (NSCLC) cell line-derived xenograft (CDX) and patient-derived xenograft (PDX) mouse models, including subcutaneous, orthotopic, metastatic, and humanized models. Conclusions: This study demonstrates the remarkable preclinical activity of bi-CD47-IT against various lung cancer models, making bi-CD47-IT a novel and promising therapeutic approach for NSCLC.
- 4 May 2026
- Published by Elsevier in American Journal of Transplantation
- Vol. 26 (6) , 1223-1242
The American Society of Transplant Surgeons and American Journal of Transplantation at 25 years: Where we have been and where we will go
- 4 May 2026
- Published by Elsevier in American Journal of Transplantation
- Vol. 26 (6) , 1223-1242
The American Society of Transplant Surgeons and American Journal of Transplantation at 25 years: Where we have been and where we will go
- 1 May 2026
- Published by Springer Nature
- p. 137-147
Biliary Atresia
- Open Access
- 25 November 2025
- Published by Wolters Kluwer Health in Annals of Surgery
- Vol. 284 (1) , 30-33
Keeping Surgeons “In the Fight”
- 25 November 2025
- Published by Wolters Kluwer Health in Annals of Surgery
- Vol. 284 (1) , 30-33
Open AccessKeeping Surgeons “In the Fight”
- 14 October 2025
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 32 (4) , 508-517
Optimizing liver transplant outcomes for colorectal liver metastases in the United States
The TransMet trial and Norwegian studies have shown excellent outcomes in highly selected patients undergoing liver transplant (LT) for unresectable colorectal liver metastases (uCRLM). Our aim is to provide an updated analysis of the current state of LT for uCRLM in the United States. Adult patients with a diagnosis of uCRLM listed for LT between December 2017 and March 2025 were identified from the United Network for Organ Sharing database and analyzed. An analysis of living donor LT (LDLT) and deceased donor LT (DDLT) was performed. During this period, 222 patients were listed, and 158 received an LT across 33 centers. Of these, 76 (48.1%) underwent LDLT, and 82 patients (51.9%) underwent DDLT. Of the 82 deceased donors, 56 (68.2%) were out-of-sequence offers. Overall, the 3-year survival and disease-free survival rates were 66.7% and 44.0%, respectively. The 3-year survival for LDLT and DDLT was 74.1% and 57.3% ( p =0.04), respectively. While these results have not yet reached the acceptable threshold established for other LT indications, they have improved and are expected to continue improving after the implementation of prioritization points. Given the potential variability of oncologic selection criteria and graft quality, we call for the standardization of nationally accepted selection criteria for listing patients for LT with uCRLM and for providing early access to high-quality organs. To achieve this, it is imperative to create, update, and maintain national databases that allow for the collection of more granular oncological variables.
- 14 October 2025
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 32 (4) , 508-517
Optimizing liver transplant outcomes for colorectal liver metastases in the United States
The TransMet trial and Norwegian studies have shown excellent outcomes in highly selected patients undergoing liver transplant (LT) for unresectable colorectal liver metastases (uCRLM). Our aim is to provide an updated analysis of the current state of LT for uCRLM in the United States. Adult patients with a diagnosis of uCRLM listed for LT between December 2017 and March 2025 were identified from the United Network for Organ Sharing database and analyzed. An analysis of living donor LT (LDLT) and deceased donor LT (DDLT) was performed. During this period, 222 patients were listed, and 158 received an LT across 33 centers. Of these, 76 (48.1%) underwent LDLT, and 82 patients (51.9%) underwent DDLT. Of the 82 deceased donors, 56 (68.2%) were out-of-sequence offers. Overall, the 3-year survival and disease-free survival rates were 66.7% and 44.0%, respectively. The 3-year survival for LDLT and DDLT was 74.1% and 57.3% ( p =0.04), respectively. While these results have not yet reached the acceptable threshold established for other LT indications, they have improved and are expected to continue improving after the implementation of prioritization points. Given the potential variability of oncologic selection criteria and graft quality, we call for the standardization of nationally accepted selection criteria for listing patients for LT with uCRLM and for providing early access to high-quality organs. To achieve this, it is imperative to create, update, and maintain national databases that allow for the collection of more granular oncological variables.
- 17 June 2025
- Published by Wolters Kluwer Health in Transplantation
- Vol. 109 (11) , 1665-1667
Robotic Surgery in Living Donor Hepatectomy and Liver Transplantation: A Critical Analysis From a Nonrobotic Surgeon’s Perspective
- 17 June 2025
- Published by Wolters Kluwer Health in Transplantation
- Vol. 109 (11) , 1665-1667
Robotic Surgery in Living Donor Hepatectomy and Liver Transplantation: A Critical Analysis From a Nonrobotic Surgeon’s Perspective
- Open Access
- 21 May 2025
- Published by Elsevier in American Journal of Transplantation
- Vol. 25 (10) , 2151-2160
Evaluation of the stability of organ procurement organization performance metrics
- 21 May 2025
- Published by Elsevier in American Journal of Transplantation
- Vol. 25 (10) , 2151-2160
Open AccessEvaluation of the stability of organ procurement organization performance metrics
- Open Access
- 8 April 2025
- Published by Elsevier in American Journal of Transplantation
- Vol. 25 (8) , 1756-1764
Association of the initial implementation of continuous distribution allocation policy with outcomes for lung transplant candidates by blood type
- 8 April 2025
- Published by Elsevier in American Journal of Transplantation
- Vol. 25 (8) , 1756-1764
Open AccessAssociation of the initial implementation of continuous distribution allocation policy with outcomes for lung transplant candidates by blood type
- Open Access
- 28 February 2025
- Published by Wolters Kluwer Health in Transplantation Direct
- Vol. 11 (3) , e1767
Thoracoabdominal Normothermic Regional Perfusion: Real-world Experience and Outcomes of DCD Liver Transplantation
Background.: Donation after circulatory death liver transplantation (DCD LT) is underused given historical outcomes fraught with ischemic cholangiopathy (IC). We aimed to assess 6-mo IC in LT from DCD via normothermic regional perfusion (NRP) compared with DCD via static cold storage (SCS). Methods.: A retrospective review of adult Maastricht-III DCD liver donors and recipients at the University of Colorado Hospital from January 1, 2017, to August 27, 2024, was performed. The 6-mo IC rate was compared between NRP and SCS. Secondary outcomes included biochemical assessments of accepted versus declined NRP liver allografts and allograft and patient survival for NRP and SCS groups. Results.: One hundred sixty-two DCD LTs (SCS = 79; NRP = 97) were performed and 150 recipients (SCS = 74; NRP = 86) reached 6-mo follow-up. Six-month IC was lower for NRP compared with SCS (1.2% versus 9.5%, P = 0.03). The Donor Risk Index (2.44 [2.02–2.82] versus 2.17 [1.97–2.30], P = 0.002) and UK DCD Risk Score (4.2 ± 2.9 versus 3.2 ± 2.3, P = 0.008) were higher for NRP versus SCS. The Liver Graft assessment Following Transplantation score was less for NRP compared with SCS (–3.3 versus –3.1, P < 0.05). There were several differences in median biochemical parameters during NRP between accepted and declined livers, including higher terminal biliary bicarbonate (22.7 [20.9–29.1] versus 10.8 [7.6–13.1] mEq/L, P = 0.004). There were no significant differences in 12-mo allograft or patient survival for NRP versus SCS. Conclusions.: NRP is a disruptive innovation that improves the utilization of DCD livers. Despite higher-risk donor-recipient pairing for NRP compared with SCS, we demonstrate a decrease in IC for NRP. These data facilitate benchmarking of thoracoabdominal NRP DCD LT and support further protocol development.
- 28 February 2025
- Published by Wolters Kluwer Health in Transplantation Direct
- Vol. 11 (3) , e1767
Open AccessThoracoabdominal Normothermic Regional Perfusion: Real-world Experience and Outcomes of DCD Liver Transplantation
Background.: Donation after circulatory death liver transplantation (DCD LT) is underused given historical outcomes fraught with ischemic cholangiopathy (IC). We aimed to assess 6-mo IC in LT from DCD via normothermic regional perfusion (NRP) compared with DCD via static cold storage (SCS). Methods.: A retrospective review of adult Maastricht-III DCD liver donors and recipients at the University of Colorado Hospital from January 1, 2017, to August 27, 2024, was performed. The 6-mo IC rate was compared between NRP and SCS. Secondary outcomes included biochemical assessments of accepted versus declined NRP liver allografts and allograft and patient survival for NRP and SCS groups. Results.: One hundred sixty-two DCD LTs (SCS = 79; NRP = 97) were performed and 150 recipients (SCS = 74; NRP = 86) reached 6-mo follow-up. Six-month IC was lower for NRP compared with SCS (1.2% versus 9.5%, P = 0.03). The Donor Risk Index (2.44 [2.02–2.82] versus 2.17 [1.97–2.30], P = 0.002) and UK DCD Risk Score (4.2 ± 2.9 versus 3.2 ± 2.3, P = 0.008) were higher for NRP versus SCS. The Liver Graft assessment Following Transplantation score was less for NRP compared with SCS (–3.3 versus –3.1, P < 0.05). There were several differences in median biochemical parameters during NRP between accepted and declined livers, including higher terminal biliary bicarbonate (22.7 [20.9–29.1] versus 10.8 [7.6–13.1] mEq/L, P = 0.004). There were no significant differences in 12-mo allograft or patient survival for NRP versus SCS. Conclusions.: NRP is a disruptive innovation that improves the utilization of DCD livers. Despite higher-risk donor-recipient pairing for NRP compared with SCS, we demonstrate a decrease in IC for NRP. These data facilitate benchmarking of thoracoabdominal NRP DCD LT and support further protocol development.